# The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma

> **NCT07645690** · EARLY_PHASE1 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Unresectable or Metastatic Clear Cell Renal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** CLEAR CAR-T cell injection

## Key facts

- **NCT ID:** NCT07645690
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07645690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07645690, "The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07645690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*